二-叔丁基吡唑烷-1,2-羧酸酯 | 146605-64-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 二-叔丁基吡唑烷-1,2-羧酸酯
• 英文名称: 1,2-bis-tert-butoxycarbonylpyrazolidine
• 英文别名: di-tert-butyl pyrazolidine-1,2-dicarboxylate；bis-BOC pyrazolidine；pyrazolidine-1,2-dicarboxylic acid di-tert-butyl ester；ditert-butyl pyrazolidine-1,2-dicarboxylate
• CAS: 146605-64-3
• 化学式: C₁₃H₂₄N₂O₄
• 分子量: 272.345
• InChiKey: VTJVHTYTEYACIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 1,2-Di-Boc-pyrazolidine
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 146605-64-3
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Molecular Weight : 272,34 g/mol
CAS-No. : 146605-64-3
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Store under inert gas.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: Powder with lumps
Colour: white, light yellow
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 3,102
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  二-叔丁基吡唑烷-1,2-羧酸酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 吡唑啶
  参考文献：
  名称：

  Synthesis, molecular modeling and biological evaluation of aza-proline and aza-pipecolic derivatives as FKBP12 ligands and their in vivo neuroprotective effects

  摘要：

  Nonimmunosuppressant ligands, exemplified by GPI 1046 (1), for the peptidyl-prolyl isomerase FKBP12 have been found to unexpectedly possess powerful neuroprotective and neuroregenerative effects in vitro and in vivo. We have extensively explored the therapeutic utility of FKBP12 ligands based on analogues of proline and pipecolic acid. As part of our ongoing program to explore novel structural classes of FKBP12 ligands, we herein wish to report a new class of FKBP12 ligands containing aza-proline and aza-pipecolic acid analogues. Details of the synthetic studies, together with biological activity will be presented. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00478-4
• 作为产物：
  描述：

  二叔丁基叠氮草酸 、 1,3-二溴丙烷 在 四乙基溴化铵 、 sodium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 生成 二-叔丁基吡唑烷-1,2-羧酸酯
  参考文献：
  名称：

  通过 N-季铵化策略制备嘧啶包埋的中型氮杂环的不同合成途径†

  摘要：

  中型杂环化合物最近因其作为蛋白质-蛋白质相互作用调节剂的潜在作用而受到广泛关注，但它们的分子多样性和合成可用性仍不足以满足需求。为了解决这些问题，我们开发了一种新的不同合成途径，用于骨架不同的含有嘧啶的中型氮杂环。我们引入了 N-季铵化的含嘧啶多杂环化合物作为通过选择性键断裂或迁移产生多样性反应的新型关键中间体，并以有效的方式制备了 14 个离散的核心骨架。通过化学信息学分析证实了所得分子框架的骨骼多样性。

  DOI：

  10.1039/c8sc04061c

文献信息

• Substituted Pyrazalones
  申请人：Lee Wen-Cherng

  公开号：US20100056505A1

  公开（公告）日：2010-03-04

  The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.

  该发明涉及式(I)的化合物作为TGFβ家族类型I受体Alk5和/或AIk 4的拮抗剂，以及使用的组合物和方法。式(I)的化合物可用于预防和/或治疗纤维化（如肾脏纤维化、肺部纤维化和肝脏纤维化）、进展性癌症或其他需要降低TGFβ家族信号活性的疾病。
• Synthesis, biological evaluation and structural determination of β-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors
  作者：Jin Hee Ahn、Mi Sik Shin、Mi Ae Jun、Sun Ho Jung、Seung Kyu Kang、Kwang Rok Kim、Sang Dal Rhee、Nam Sook Kang、Sun Young Kim、Sang-Kwon Sohn、Sung Gyu Kim、Mi Sun Jin、Jie Oh Lee、Hyae Gyeong Cheon、Sung Soo Kim

  DOI：10.1016/j.bmcl.2007.01.111

  日期：2007.5

  Inhibitors of dipeptidyl peptidase IV (DPP-IV) have been shown to be effective treatments for type 2 diabetes. A series of beta-aminoacyl-containing cyclic hydrazine derivatives were synthesized and evaluated as DPP-IV inhibitors. One member of this series, (R)-3-amino-1-(2-benzoyl-1,2-diazepan-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one (10f), showed potent in vitro activity, good selectivity and in

  二肽基肽酶IV（DPP-IV）抑制剂已被证明是治疗2型糖尿病的有效方法。合成了一系列含β-氨基酰基的环状肼衍生物，并作为DPP-IV抑制剂进行了评估。该系列的一个成员（R）-3-氨基-1-（2-苯甲酰基-1,2-二氮杂-1-基）-4-（2,4,5-三氟苯基）丁-1-（10f ）在小鼠模型中显示出强大的体外活性，良好的选择性和体内功效。另外，化合物10f的结合模式通过X射线晶体学确定。
• Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DP-IV) inhibitors
  作者：Jin Hee Ahn、Jin Ah Kim、Hye-Min Kim、Hyuk-Man Kwon、Sun-Chul Huh、Sang Dal Rhee、Kwang Rok Kim、Sung-Don Yang、Sung-Dae Park、Jae Mok Lee、Sung Soo Kim、Hyae Gyeong Cheon

  DOI：10.1016/j.bmcl.2005.01.020

  日期：2005.3

  A new series of pyrazolidine derivatives was synthesized and evaluated for their ability to inhibit dipeptidyl peptidase IV (DP-IV). Compound 9i was the most active in this series, exhibited IC50 value of 1.56 microM and ED50 value of 80 mg/kg (in vivo DP-IV inhibition; po).

  合成了一系列新的吡唑烷衍生物，并评估了它们抑制二肽基肽酶IV（DP-IV）的能力。化合物9i是该系列中活性最高的化合物，IC50值为1.56 microM，ED50值为80 mg / kg（体内DP-IV抑制；口服）。
• A convenient synthesis of pyrazolidine and 3-amino-6,7-dihydro-1H,5H-pyrazolo[1,2-a] pyrazol-1-one
  作者：Eric E. Boros、Frédéric Bouvier、Sab Randhawa、Michael H. Rabinowitz

  DOI：10.1002/jhet.5570380310

  日期：2001.5

  A convenient four-step synthesis of the aminobicyclopyrazolone hydrochloride 1·HC1 was achieved starting from di-tert-butyl hydrazodiformate (8). The route entails cyclization of 8 with 1,3-dibromopropane under phase transfer conditions followed by deprotection of 1,2-di-tert-butoxycarbonylpyrazolidine (9) to give pyrazolidine hydrochloride (2·HC1). Cyanoacetylation of the latter and ring closure of

  从肼基二甲酸二叔丁酯（8）开始，完成了氨基双环吡唑酮盐酸盐1 ·HCl的便捷四步合成。该路线需要在相转移条件下用1,3-二溴丙烷将8环化，然后将1,2-二叔丁氧基羰基吡唑烷（9）脱保护，得到吡唑烷盐酸盐（2 ·HCl）。后者的乙酰乙酰基化和所得氰基乙酰基吡唑烷（7）的闭环得到1·HCl。此新颖的合成方法避免了吡唑烷（2）的蒸馏和快速色谱分离，从而提供1的盐酸盐 总专利收率为6％，而总收率则为35-46％。
• 피리미딘을 포함하는 폴리헤테로사이클 유도체 및 이의 용도
  申请人：서울대학교산학협력단

  公开号：KR20230141050A

  公开（公告）日：2023-10-10

  본 발명은 암질환을 치료하는 의약품의 제조에 유용한 신규한 폴리헤테로사이클 유도체에 관한 것으로서, 보다 상세하게는 우수한 종양 성장 억제 효과를 갖는 피리미딘을 포함하는 폴리헤테로사이클 유도체, 또는 이의 약제학적으로 허용가능한 염 또는 이성질체, 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물에 관한 것이다.

  本发明涉及一种用于制备治疗癌症药物的新型多杂环衍生物，更具体地，涉及一种包含嘧啶环结构且具有良好肿瘤生长抑制作用的多杂环衍生物，或其药学上可接受的盐或同晶型，以及包含该化合物作为有效成分用于预防或治疗癌症的药学组合物。